Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
17.56
+0.32 (1.86%)
At close: Jul 2, 2026, 4:00 PM EDT
17.60
+0.04 (0.23%)
After-hours: Jul 2, 2026, 7:57 PM EDT
Intellia Therapeutics Stock Forecast
Stock Price Forecast
According to 22 analysts polled by S&P Global, Intellia Therapeutics stock has a consensus rating of "Buy" and an average price target of $26.63. The average 1-year stock price forecast is 51.65% higher than the current stock price, while the lowest is $8.00 (-54.44%) and the highest is $95 (+441.00%).
Price Target: $26.63 (+51.65%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Intellia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 11 | 13 | 13 | 11 | 10 |
| Buy | 2 | 1 | 1 | 1 | 1 | 2 |
| Hold | 11 | 11 | 9 | 9 | 9 | 8 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 25 | 25 | 25 | 25 | 23 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $49 | Buy | Maintains | $49 | +179.04% | Jun 16, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Maintains $19 | Hold | Maintains | $19 | +8.20% | Jun 16, 2026 |
| Goldman Sachs | Goldman Sachs | Sell Maintains $9 | Sell | Maintains | $9 | -48.75% | Jun 15, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Hold Maintains $12 | Hold | Maintains | $12 | -31.66% | Jun 15, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 15, 2026 |
Financial Forecast
Revenue This Year
59.97M
from 67.67M
Decreased by -11.38%
Revenue Next Year
265.93M
from 59.97M
Increased by 343.42%
EPS This Year
-3.17
from -3.81
EPS Next Year
-1.80
from -3.17
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 100.0M | ||
| Avg | 60.0M | ||
| Low | 15.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 47.8% | ||
| Avg | -11.4% | ||
| Low | -77.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -2.76 | ||
| Avg | -3.17 | ||
| Low | -3.75 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |